Compare Biogen Inc (BIIB) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Star Bulk Carriers Corp — how do they compare? Biogen Inc trades at $193.38 (market cap $28.34B), while Star Bulk Carriers Corp trades at $26.33 (market cap $2.96B). The key difference: Biogen Inc is far larger — about 9.6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.88% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | SBLK | |
|---|---|---|
Market Cap | $28.34B | $2.96B |
Sector | Health | Industrials |
52-Week High | $216.63 | $28.21 |
52-Week Low | $122.68 | $16.79 |
Enterprise Value | $30.62B | $3.66B |
Dividend Yield | — | 3.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Star Bulk Carriers (SBLK) trades at $26.54, up 0.72% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with Q1 2026 earnings beating expectations at $0.56 EPS versus $0.475 expected, while maintaining a healthy 13.01% net income margin. Recent news highlights robust dry bulk rates supporting potential double-digit dividend yields, with the company's modernizing fleet and opportunistic asset sales strengthening the balance sheet.
SBLK presents a compelling opportunity with strong cash flow generation and shareholder returns, though investors face risks from spot rate volatility and cyclical shipping demand. Wall Street maintains bullish sentiment with 14 buy ratings versus 2 sells, while technical indicators show potential resistance near $27 levels. The company's disciplined capital allocation and fleet renewal strategy provide upside potential if dry bulk markets remain favorable.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
